Literature DB >> 20401222

Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?

B Law1, N Macdonald, J Langley, I Mitchell, D Stephens, E Wang, J Robinson, F Boucher, J McDonald, S Dobson.   

Abstract

Entities:  

Year:  1998        PMID： 20401222      PMCID： PMC2851304          DOI： 10.1093/pch/3.6.402

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN： 1205-7088            Impact factor:   2.253


× No keyword cloud information.
  10 in total

1.  Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study.

Authors:  J M Langley; E E Wang; B J Law; D Stephens; F D Boucher; S Dobson; J McDonald; N E MacDonald; I Mitchell; J L Robinson
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

2.  Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life.

Authors:  C J Holberg; A L Wright; F D Martinez; C G Ray; L M Taussig; M D Lebowitz
Journal:  Am J Epidemiol       Date:  1991-06-01       Impact factor: 4.897

3.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

4.  Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group.

Authors: 
Journal:  Pediatrics       Date:  1997-01       Impact factor: 7.124

5.  Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database.

Authors:  B J Law; E E Wang; N MacDonald; J McDonald; S Dobson; F Boucher; J Langley; J Robinson; I Mitchell; D Stephens
Journal:  Pediatrics       Date:  1997-03       Impact factor: 7.124

6.  Preterm twins and triplets. A high-risk group for severe respiratory syncytial virus infection.

Authors:  E A Simoes; S J King; M V Lehr; J R Groothuis
Journal:  Am J Dis Child       Date:  1993-03

7.  Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

Authors:  J R Groothuis; E A Simoes; M J Levin; C B Hall; C E Long; W J Rodriguez; J Arrobio; H C Meissner; D R Fulton; R C Welliver
Journal:  N Engl J Med       Date:  1993-11-18       Impact factor: 91.245

8.  Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection.

Authors:  E E Wang; B J Law; D Stephens
Journal:  J Pediatr       Date:  1995-02       Impact factor: 4.406

9.  Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada.

Authors:  L Navas; E Wang; V de Carvalho; J Robinson
Journal:  J Pediatr       Date:  1992-09       Impact factor: 4.406

10.  Parental smoking, presence of older siblings, and family history of asthma increase risk of bronchiolitis.

Authors:  K M McConnochie; K J Roghmann
Journal:  Am J Dis Child       Date:  1986-08
  10 in total
  19 in total

1.  Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.

Authors:  Kelly A Smart; Krista L Lanctôt; Bosco A Paes
Journal:  Can Fam Physician       Date:  2010-10       Impact factor: 3.275

2.  Letters to the Editor.

Authors:  I Mitchell; B Paes; K Lanctot; Rupesh Chawla; Aaron Chiu; Marianna Mitchell; Cecil Ojah; April Price; Sandra Seigel; Amanda Symington
Journal:  Paediatr Child Health       Date:  2015 Nov-Dec       Impact factor: 2.253

3.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

4.  Use of palivizumab in children with congenital heart disease.

Authors: 
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

5.  Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants.

Authors: 
Journal:  Paediatr Child Health       Date:  1999-10       Impact factor: 2.253

6.  The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study.

Authors:  Michelle L Butt; Amanda Symington; Marianne Janes; Louann Elliott; Susan Steele; Bosco A Paes
Journal:  Eur J Pediatr       Date:  2010-12-22       Impact factor: 3.183

7.  Prevention of respiratory syncytial virus infection.

Authors:  L Samson
Journal:  Paediatr Child Health       Date:  2009-10       Impact factor: 2.253

8.  A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).

Authors:  B Paes; I Mitchell; A Li; K L Lanctôt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-01       Impact factor: 3.267

9.  Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection.

Authors:  Thierry Lacaze-Masmonteil; Juergen Seidenberg; Ian Mitchell; Veerle Cossey; Martin Cihar; Michal Csader; Rienk Baarsma; Marques Valido; Paul F Pollack; Jessie R Groothuis
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

10.  Risk factors for severe respiratory syncytial virus lower respiratory tract infection.

Authors:  Constanze Sommer; Bernhard Resch; Eric A F Simões
Journal:  Open Microbiol J       Date:  2011-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.